Allogene Therapeutics advances ALLO-329 using Dagger technology to target autoimmune disease

Traders Union
All News
Companies
Allogene advances ALLO-329 therapy

Top Stories

Editors' Picks

Crypto News

Financial News

Market Voices

Billionaires

Companies

Broker News

Regulators News

Olesia Kramarenko

12.03.2026

Allogene Therapeutics advances ALLO-329 using Dagger technology to target autoimmune disease — Allogene advances ALLO-329 therapy

Allogene Therapeutics unveils progress on ALLO-329, an investigational off-the-shelf AlloCAR T product aimed at treating autoimmune diseases with its proprietary Dagger technology.

The company asserts that this new approach could help reset the immune system, potentially broadening access to cell therapy and transforming patient care. Allogene Therapeutics continues to focus on next-generation therapeutic modalities to expand the horizons of allogeneic cell therapy in complex disease areas.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

The company's ongoing commitment to advancing CAR T therapies builds on earlier announcements regarding its participation in initiatives such as the Virtual Oncology Summit, where pipeline developments were a focal point. Recent progress in tackling autoimmune diseases further reinforces the sense of breakthrough hope for severe autoimmune disease patients, underscoring Allogene Therapeutics' sustained pursuit of innovative solutions in the cell therapy landscape.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

Bitcoin or Ferrari: Which investment is better?

By Mira Kyivska
22 hours ago

Bitcoin or Ferrari: Which investment is better?

Editors' Picks

Strategy sells Bitcoin: Small sale tests market confidence

By Mira Kyivska
Yesterday

Strategy sells Bitcoin: Small sale tests market confidence

Editors' Picks

Ledger vs. Trezor: Search for ideal crypto wallet

By Mikhail Vnuchkov
05.06.2026

Ledger vs. Trezor: Search for ideal crypto wallet

Editors' Picks

All Editors' Top Picks

Latest Allogene News

Allogene Therapeutics targets 1 in 3 LBCL relapses with ALPHA3 trial and MRD testing

By Artem Shendetskii
03.06.2026

Allogene Therapeutics targets 1 in 3 LBCL relapses with ALPHA3 trial and MRD testing

Companies

Allogene Therapeutics reviews investigational cema-cel use and early ALPHA3 safety data for community outpatients

By Eugene Komchuk
02.06.2026

Allogene Therapeutics reviews investigational cema-cel use and early ALPHA3 safety data for community outpatients

Companies

Allogene Therapeutics to present pipeline and strategy update at Jefferies Global Healthcare Conference

By Dmytro Kharkov
29.05.2026

Allogene Therapeutics to present pipeline and strategy update at Jefferies Global Healthcare Conference

Companies

All Allogene News

Mira Kyivska
22 hours ago

Bitcoin or Ferrari: Which investment is better?

Mira Kyivska
Yesterday

Strategy sells Bitcoin: Small sale tests market confidence

Mikhail Vnuchkov
05.06.2026

Ledger vs. Trezor: Search for ideal crypto wallet

Oleg Tkachenko
04.06.2026

Trading thin air: Why Binance is closing its NFT marketplace

Eugene Komchuk
03.06.2026

Bitcoin without investors: Why IPOs are winning attention

Jose Antonio Gastelum
5 min ago

Stephan Livera: Building wealth with bitcoin requires long-term commitment

Igor Krasulya
5 min ago

€4 million capital markets transaction completed rapidly, Michael Geike points out

Daria Chernytska
35 min ago

Christopher Jaszczynski: No. 1 Bitcoin YouTube channel worldwide by average video views

Hanna Syniavska
50 min ago

Joao Wedson: Ethereum market cap equals Tether for first time

Oleg Tkachenko
1 hour ago

OPEC+ output hike seen as paper barrels, Mohamed A. El-Erian notes

Weekly Top Bonuses

Capitalcore

up to $2,500
deposit bonus for all clients

Your capital is at risk.

Top News

Olga Shendetskaya
22 min ago

Oil rises above $97 after new Israel-Iran exchange of strikes

Oil rises above $97 after new Israel-Iran exchange of strikes

Eugene Komchuk
1 hour ago

Justin Sun crypto exchange halts trading of Trump family stablecoin

Justin Sun crypto exchange halts trading of Trump family stablecoin

Olga Shendetskaya
05.06.2026

Strong May jobs report complicates Fed rate outlook

Strong May jobs report complicates Fed rate outlook

Hanna Syniavska
05.06.2026

Bitcoin falls below $62,000 after strong U.S. jobs report

Bitcoin falls below $62,000 after strong U.S. jobs report

Eugene Komchuk
05.06.2026

Traders Union research: 41% of investors bet on a single asset

Traders Union research: 41% of investors bet on a single asset

Top 5 companies for you

United States

Live News

Anton Kharitonov
Now

Apple remains under pressure ahead of WWDC 2026

Anton Kharitonov
Now

Bitcoin declines as investors reduce long positions

Anton Kharitonov
Now

WTI declines again amid demand concerns

Dmytro Kharkov
Now

SpaceX IPO could weigh on Tesla as investors chase new growth story

Anton Kharitonov
Now

Natural gas tests strong resistance amid demand recovery and LNG market risks

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.